Maravai Lifesciences Holdings Stock Cash Per Share
| MRVI Stock | USD 4.96 0.14 2.90% |
Maravai Lifesciences Holdings fundamentals help investors to digest information that contributes to Maravai Lifesciences' financial success or failures. It also enables traders to predict the movement of Maravai Stock. The fundamental analysis module provides a way to measure Maravai Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Maravai Lifesciences stock.
Maravai |
Maravai Lifesciences Holdings Company Cash Per Share Analysis
Maravai Lifesciences' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Maravai Lifesciences Cash Per Share | 4.69 X |
Most of Maravai Lifesciences' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Maravai Lifesciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Maravai Lifesciences Holdings has a Cash Per Share of 4.69 times. This is 7.82% higher than that of the Life Sciences Tools & Services sector and 8.31% higher than that of the Health Care industry. The cash per share for all United States stocks is 6.39% higher than that of the company.
Maravai Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Maravai Lifesciences' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Maravai Lifesciences could also be used in its relative valuation, which is a method of valuing Maravai Lifesciences by comparing valuation metrics of similar companies.Maravai Lifesciences is currently under evaluation in cash per share category among its peers.
Maravai Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.81) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 666.6 M | ||||
| Shares Outstanding | 141.84 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 98.63 % | ||||
| Number Of Shares Shorted | 8.22 M | ||||
| Price To Earning | 7.79 X | ||||
| Price To Book | 1.98 X | ||||
| Price To Sales | 4.40 X | ||||
| Revenue | 288.94 M | ||||
| Gross Profit | 714.04 M | ||||
| EBITDA | 712.41 M | ||||
| Net Income | (119.03 M) | ||||
| Cash And Equivalents | 617.45 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 610.97 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 7.22 X | ||||
| Book Value Per Share | 2.44 X | ||||
| Cash Flow From Operations | 126.22 M | ||||
| Short Ratio | 6.63 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.22) X | ||||
| Target Price | 9.73 | ||||
| Number Of Employees | 580 | ||||
| Beta | 0.024 | ||||
| Market Capitalization | 1.22 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 285.74 M | ||||
| Working Capital | 612.44 M | ||||
| Net Asset | 1.49 B |
About Maravai Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Maravai Lifesciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maravai Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maravai Lifesciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Maravai Lifesciences Piotroski F Score and Maravai Lifesciences Altman Z Score analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.